|
1
|
Benjamin EJ, Virani SS, Callaway CW,
Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling
FN, Deo R, et al: Heart disease and stroke statistics-2018 update:
A report from the American heart association. Circulation.
137:e67–e492. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Philipps J, Thomalla G, Glahn J, Schwarze
M and Röther J: Treatment of progressive stroke with
tirofiban-experience in 35 patients. Cerebrovasc Dis. 28:435–438.
2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Siegler JE, Boehme AK, Albright KC, George
AJ, Monlezun DJ, Beasley TM and Martin-Schild S: A proposal for the
classification of etiologies of neurologic deterioration after
acute ischemic stroke. J Stroke Cerebrovasc Dis. 22:e549–e556.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tada Y, Uno M, Matsubara S, Suzue A,
Shimada K, Morita N, Harada M and Nagahiro S: Reversibility of
ischemic findings on 3-T T2*-weighted imaging after emergency
superficial temporal artery-middle cerebral artery anastomosis in
patients with progressive ischemic stroke -two case reports. Neurol
Med Chir (Tokyo). 50:1006–1011. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Derflinger S, Fiebach JB, Böttger S,
Haberl RL and Audebert HJ: The progressive course of neurological
symptoms in anterior choroidal artery infarcts. Int J Stroke.
10:134–137. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Eriksson M, Stecksén A, Glader EL,
Norrving B, Appelros P, Hulter Åsberg K, Stegmayr B, Terént A and
Asplund K: Riks-Stroke Collaboration. Discarding heparins as
treatment for progressive stroke in Sweden 2001 to 2008. Stroke.
41:2552–2558. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhang C, Zhao S, Zang Y, Gu F, Mao S, Feng
S, Hu L and Zhang C: The efficacy and safety of
Dl-3n-butylphthalide on progressive cerebral infarction: A
randomized controlled STROBE study. Medicine (Baltimore).
96(e7257)2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fullard JF: The role of the platelet
glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm
Des. 10:1567–1576. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Choudhri TF, Hoh BL, Zerwes HG,
Prestigiacomo CJ, Kim SC, Connolly ES Jr, Kottirsch G and Pinsky
DJ: Reduced microvascular thrombosis and improved outcome in acute
murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet
aggregation. J Clin Invest. 102:1301–1310. 1998.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zi W, Song J, Kong W, Huang J, Guo C, He
W, Yu Y, Zhang B, Geng W, Tan X, et al: Tirofiban for stroke
without large or medium-sized vessel occlusion. N Engl J Med.
388:2025–2036. 2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Van't Hof AW, Ten Berg J, Heestermans T,
Dill T, Funck RC, van Werkum W, Dambrink JH, Suryapranata H, van
Houwelingen G, Ottervanger JP, et al: Prehospital initiation of
tirofiban in patients with ST-elevation myocardial infarction
undergoing primary angioplasty (on-TIME 2): A multicentre,
double-blind, randomised controlled trial. Lancet. 372:537–546.
2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wu C, Sun C, Wang L, Lian Y, Xie N, Huang
S, Zhao W, Ren M, Wu D, Ding J, et al: Low-dose tirofiban treatment
improves neurological deterioration outcome after intravenous
thrombolysis. Stroke. 50:3481–3487. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Du Y, Li Y, Duan Z, Ma C, Wang H, Liu R,
Li S and Lian Y: The efficacy and safety of intravenous tirofiban
in the treatment of acute ischemic stroke patients with early
neurological deterioration. J Clin Pharm Ther. 47:2350–2359.
2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kellert L, Hametner C, Rohde S, Bendszus
M, Hacke W, Ringleb P and Stampfl S: Endovascular stroke therapy.
Stroke. 44:1453–1455. 2013.
|
|
15
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: an updated guideline for
reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sterne JA, Hernán MA, Reeves BC, Savović
J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT,
Boutron I, et al: ROBINS-I: A tool for assessing risk of bias in
non-randomised studies of interventions. BMJ.
355(i4919)2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Powers WJ, Rabinstein AA, Ackerson T,
Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk
BM, Hoh B, et al: Guidelines for the early management of patients
with acute ischemic stroke: 2019 update to the 2018 guidelines for
the early management of acute ischemic stroke: A guideline for
healthcare professionals from the American heart
association/American stroke association. Stroke. 50:e344–e418.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Quinn TJ, Lees KR, Hardemark HG, Dawson J
and Walters MR: Initial experience of a digital training resource
for modified Rankin scale assessment in clinical trials. Stroke.
38:2257–2261. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mahoney FI and Barthel DW: Functional
evaluation: The barthel index. Md State Med J. 14:61–65.
1965.PubMed/NCBI
|
|
20
|
Born GV: Aggregation of blood platelets by
adenosine diphosphate and its reversal. Nature. 194:927–929.
1962.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Salzman EW: Measurement of platelet
adhesiveness. A simple in vitro technique demonstrating an
abnormality in von Willebrand's disease. J Lab Clin Med.
62:724–735. 1963.PubMed/NCBI
|
|
22
|
Higgins JP, Altman DG, Gøtzsche PC, Jüni
P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L and Sterne JA:
The cochrane collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343(d5928)2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Han B, Ma T, Liu Z, Wu Y, Tan W, Sun S, Li
X, Shao C, Tang D and Sun J: Efficacy and safety of tirofiban in
clinical patients with acute ischemic stroke. Front Neurol.
12(785836)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhao W, Li S, Li C, Wu C, Wang J, Xing L,
Wan Y, Qin J, Xu Y, Wang R, et al: Effects of tirofiban on
neurological deterioration in patients with acute ischemic stroke.
JAMA Neurol. 81:594–602. 2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ruiqing C, Yuqing D and Pengcheng L:
Effect of tirofiban and dual antiplatelet therapy in patients with
acute progressive cerebral infarction with hyperthrombolytic time
window. J Clin Exper Med. 23:1013–1017. 2024.(In Chinese).
|
|
26
|
Lusheng S and Jiang X: Effects of
clopidogrel combined with tirofiban on inflammatory indexes and
platelet function in progressive stroke. Special Health. 63–64.
2022.(In Chinese).
|
|
27
|
Jingjing L, Lianping L, Yakun G and Jing
P: Observation on the clinical efficacy of tirofiban in the
treatment of acute progressive cerebral infarction. Drug
Evaluation. 21:117–120. 2024.(In Chinese).
|
|
28
|
Caixia L, Xiaokai W and Xiaoli L: Effect
of tirofiban combined with ticagrelor on neurological function and
recurrence in patients with acute progressive cerebral infarction.
Henan Medical Research. 1086–1090. 2024.(In Chinese).
|
|
29
|
Yanxiao L, Qing C, Huanhuan W, Aixia S and
Qian X: Analysis of the clinical efficacy and safety of tirofiban
injection combined with aspirin and clopidogrel in patients with
acute progressive cerebral infarction. Chin J Med. 902–905.
2024.(In Chinese).
|
|
30
|
Xiaochen L, Yongjiang L and Rongying W:
The effect of tirofiban on matrix metalloproteinase levels in
patients with acute progressive cerebral infarction. Chin J
Clinicians. 48:680–683. 2020.(In Chinese).
|
|
31
|
Zhihua X, Yunming T and Hong L: Efficacy
of tirofiban combined with clopidogrel bisulfate in the treatment
of progressive ischemic stroke and its impact on neurological
function. Chin J Clin Rational Drug Use. 17:2024.(In Chinese).
|
|
32
|
Shujuan D: The effect of tirofiban on
acute progressive cerebral infarction beyond the thrombolytic time
window: A title for a research paper. Clin Med. 44:105–107.
2024.(In Chinese).
|
|
33
|
Hui B, Huiyun N and Yan L: Analysis of
safety of tirofiban for patients with acute progressive cerebral
infarction. Chin J Modern Drug Appl. 18:66–68. 2024.(In
Chinese).
|
|
34
|
Zhongzheng L, Zheng B, Fangkun Z, Rong Y
and Xiaotan W: Effects of tirofiban on neurological function and
platelet function in patients with progressive cerebral infarction.
J Brain Nervous System Dis. 433–436. 2020.(In Chinese).
|
|
35
|
Du N, Wang LX, Liu YL, Yin XL, Zhao JS and
Yang L: Effect of tirofiban in treating patients with progressive
ischemic stroke. Eur Rev Med Pharmacol Sci. 26:2098–2105.
2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wang H, Li X, Liu C, Huang S, Liang C and
Zhang M: Effects of oral antiplatelet agents and tirofiban on
functional outcomes of patients with non-disabling minor acute
ischemic stroke. J Stroke Cerebrovasc Dis.
29(104829)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhang ZM, Lin ZH and Zhu GL: Tirofiban in
the treatment of cancer-associated ischemic stroke. Eur Rev Med
Pharmacol Sci. 27:3590–3596. 2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhang H, Lin F, Zhao Y, Chang W, Liu H,
Yin J and Li L: Assessing the efficacy and safety of tirofiban in
combination with dual-antiplatelet therapy in progressive ischemic
stroke patients. J Cardiovasc Pharmacol. 78:448–452.
2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhengfei M, Ping Z, Gang Z and Yongxing S:
Therapeutic effect of tirofiban on patients with acute
non-intracranial large vessel occlusive progressive cerebral
infarction and its safety. Chin J Cardiovasc Rehab Med. 29:665–668.
2020.(In Chinese).
|
|
40
|
Wenzhou J: Clinical efficacy and safety of
tirofiban in the treatment of acute progressive cerebral
infarction: A study. Chin J Clinicians. 48:1433–1435. 2020.(In
Chinese).
|
|
41
|
Tang L, Tang X and Yang Q: The application
of tirofiban in the endovascular treatment of acute ischemic
stroke: A meta-analysis. Cerebrovasc Dis. 50:121–131.
2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lu WZ, Lin HA, Hou SK, Bai CH and Lin SF:
Efficacy and safety of tirofiban in patients with acute ischemic
stroke treated with endovascular thrombectomy: A frequentist and
Bayesian meta-analysis. Vascul Pharmacol.
153(107244)2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Liu C, Yang X, Liu M, Wang J and Li G:
Meta-analysis of the efficacy and safety of tirofiban in patients
with acute ischaemic stroke undergoing mechanical thrombectomy.
Clin Neurol Neurosurg. 228(107702)2023.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Shi H, Hou MM, Ren G, He ZF, Liu XL, Li XY
and Sun B: Tirofiban for acute ischemic stroke patients receiving
intravenous thrombolysis: A systematic review and meta-analysis.
Cerebrovasc Dis. 52:587–596. 2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Niu J, Ding Y, Zhai T, Ju F, Lu T, Xue T,
Yin D, Fang D, Chen H and Zhao G: The efficacy and safety of
tirofiban for patients with acute ischemic stroke: A protocol for
systematic review and a meta-analysis. Medicine (Baltimore).
98(e14673)2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Behari S, Singh S and Bhaisora KS:
Ischemic stroke associated with ankylosing spondylitis: An integral
part of disease spectrum, or a natural consequence of progressive
infirmity? Acta Neurochir (Wien). 160:959–961. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhao G, Lin F, Wang Z, Shao X, Gong Y,
Zhang S, Cui Y, Yang D, Lei H, Cheng Z, et al: Dual antiplatelet
therapy after intravenous thrombolysis for acute minor ischemic
stroke. Eur Neurol. 82:93–98. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Yagudina RI, Kulikov AY, Krylov VA,
Solovieva EY and Fedin AI: Pharmacoeconomic analysis of the
neuroprotective medicines in the treatment of ischemic stroke. Zh
Nevrol Psikhiatr Im S S Korsakova. 119:60–68. 2019.PubMed/NCBI View Article : Google Scholar : (In Russian).
|
|
49
|
Gruber P, Hlavica M, Berberat J, Victor
Ineichen B, Diepers M, Nedeltchev K, Kahles T and Remonda L: Acute
administration of tirofiban versus aspirin in emergent carotid
artery stenting. Interv Neuroradiol. 25:219–224. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Yang M, Huo X, Miao Z and Wang Y: Platelet
glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute
ischemic stroke. Drugs. 79:515–529. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Huo X, Yang M, Ma N, Gao F, Mo D, Li X,
Wang A, Wang Y and Miao Z: Safety and efficacy of tirofiban during
mechanical thrombectomy for stroke patients with preceding
intravenous thrombolysis. Clin Interv Aging. 15:1241–1248.
2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Field TS and Benavente OR: Current status
of antiplatelet agents to prevent stroke. Curr Neurol Neurosci Rep.
11:6–14. 2011.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Feng L, Liu J, Liu Y, Chen J, Su C, Lv C
and Wei Y: Tirofiban combined with urokinase selective
intra-arterial thrombolysis for the treatment of middle cerebral
artery occlusion. Exp Ther Med. 11:1011–1016. 2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Seo JH, Jeong HW, Kim ST and Kim EG:
Adjuvant tirofiban injection through deployed solitaire stent as a
rescue technique after failed mechanical thrombectomy in acute
stroke. Neurointervention. 10:22–27. 2015.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Weimar C, Mieck T, Buchthal J, Ehrenfeld
CE, Schmid E and Diener HC: German Stroke Study Collaboration.
Neurologic worsening during the acute phase of ischemic stroke.
Arch Neurol. 62:393–397. 2005.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Zanaty M, Osorno-Cruz C, Byer S, Roa JA,
Limaye K, Ishii D, Nakagawa D, Torner J, Yongjun L,
Ortega-Gutiérrez S, et al: Tirofiban protocol protects against
delayed cerebral ischemia: A case-series study. Neurosurgery.
87:E552–E556. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Yates YJ, Farias CL, Kazmier FR, Puckett
CL and Concannon MJ: The effect of tirofiban on microvascular
thrombosis: Crush model. Plast Reconstr Surg. 116:205–208.
2005.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Mingming Z and Qizhi F: Observation on the
clinical efficacy of tirofiban combined with antiplatelet drugs in
the treatment of transient ischemic attack. J Clin Rational Drug
Use. 13:31–32. 2020.(In Chinese).
|
|
59
|
Siebler M, Hennerici MG, Schneider D, von
Reutern GM, Seitz RJ, Röther J, Witte OW, Hamann G, Junghans U,
Villringer A and Fiebach JB: Safety of tirofiban in acute ischemic
stroke: The SaTIS trial. Stroke. 42:2388–2392. 2011.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Wang Y, Wang Y, Zhao X, Liu L, Wang D,
Wang C, Wang C, Li H, Meng X, Cui L, et al: Clopidogrel with
aspirin in acute minor stroke or transient ischemic attack. N Engl
J Med. 369:11–19. 2013.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Johnston SC, Easton JD, Farrant M, Barsan
W, Conwit RA, Elm JJ, Kim AS, Lindblad AS and Palesch YY:
Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.
N Engl J Med. 379:215–225. 2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Chen HS, Cui Y, Wang XH, Ma YT, Han J,
Duan YJ, Lu J, Shen LY, Liang Y, Wang WZ, et al: Clopidogrel plus
aspirin vs aspirin alone in patients with acute mild to moderate
stroke: The ATAMIS randomized clinical trial. JAMA Neurol.
81:450–460. 2024.PubMed/NCBI View Article : Google Scholar
|
